Non-myeloablative (NMA) allogeneic donor SCT for patients with relapsed lymphoma is associated with lower treatment-related mortality (TRM). However, the impact of conditioning intensity on post transplant infections remains unclear. We evaluated infections in 141 consecutive patients with lymphoma who were allografted using NMA (n ¼ 76) or myeloablative (MA; n ¼ 65) conditioning regimens. Using infection incidence density per 1000 patient days, we accounted for all infectious episodes during the first post transplant year. Before neutrophil engraftment, the NMA cohort had a 53% lower rate of bacterial infection (relative risk ¼ 0.47; P ¼ 0.06), whereas after engraftment the density of bacterial infections was similar in the two groups. In the first month, both invasive fungal infections and viral infections were twofold less frequent (P ¼ 0.22; P ¼ 0.06) in NMA patients. Late viral and fungal infections as well as CMV reactivation were infrequent after either conditioning intensity. The 1-year infection-related mortality was significantly lower after NMA conditioning (NMA 9% (3-16%) vs MA 22% (11-40%); P ¼ 0.03). NMA allogeneic transplantation for lymphoma patients results in substantially fewer early infections and lower infection-related deaths, although the similar frequency of later infections suggests that immune reconstitution is delayed with either conditioning intensity.
Introduction
Patients with relapsed or advancing non-Hodgkin's and Hodgkin's lymphomas may be successfully treated with allogeneic donor hematopoietic SCT (HSCT). Allotransplantation may be curative for some patients because of the antilymphoma effect of the graft, however, the transplantrelated mortality (TRM) rate of myeloablative (MA) HSCT is reported to be 25-50%. [1] [2] [3] [4] [5] Infections are frequent complications following HSCT and vary widely with the donor type, conditioning regimen, the immunosuppressive therapy used to prevent and treat GVHD as well as host factors such as age, underlying malignancy and presence of comorbidities. [6] [7] [8] [9] [10] [11] [12] Non-myeloablative (NMA) conditioning has been explored to decrease acute toxicities and shorten neutropenia and yet maintain a GVL effect. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The wider use of NMA regimens allows patients with less than adequate organ function, preceding fungal infections, or older age to receive allografts.
Patients with lymphoma represent a distinct population as they often have inherent immunodeficiency and commonly are heavily pretreated with immune modulating agents such as fludarabine (Flu), rituximab, corticosteroids or alemtuzumab. Thus, the infection frequency and outcomes of lymphoma patients may be different from other HSCT recipients. The results of published analyses of infections following allografts vary widely and are largely limited to cohorts of patients with heterogeneous diseases. [7] [8] [9] 11, 12, 16, 17 We examined the differences in etiologies and timing of bacterial, viral and fungal infections and their risk factors in 141 patients with lymphoma after either NMA or MA conditioning allografts. 5 
Patients and methods

Data collection
Using prospectively collected data from the University of Minnesota Blood and Marrow Transplantation Database, we identified 141 consecutive patients with lymphoma who underwent allogeneic HSCT between 1997 and . A review of all available medical and microbiological records supplemented the database. We identified all infectious episodes, pathogens and outcome during three time periods: days 0-30 (peritransplant), days 31-100 (early post transplant period) and days 101-365 (late post transplant period).
Definitions
The day of infection was calculated from the day of stem cell infusion (d0). Fatal infections and infection-related mortality (IRM) were defined as death within 30 days of an identified infection without graft failure or disease relapse. 16 Neutropenic fevers without an identified pathogen were not enumerated as infectious episodes. Catheterassociated infections were defined as two positive blood cultures drawn through a central venous catheter in patients with otherwise unexplained fever 438 1C. 17 Infections were grouped into Gram-negative and Gram-positive bacteremia and pneumonia, catheter-associated infections, invasive fungal infections (IFI: aspergillosis, systemic candidiasis, molds or probable fungal infections 18 ), CMV infections, respiratory viral, herpetic (herpes simplex virus, varicella-zoster virus, HHV6 virus) and other viral infections (rotavirus, adenovirus, hepatitis viruses). Specific time intervals were required to identify recurrent infections: bacteremia (interval of 7 days); pneumonia and Clostridium difficile colitis (30 days); IFI (90 days); and CMV reactivation (60 days). 27 CMV reactivation using pp65 antigenemia was based on the detection of X2 direct fluorescence antibody-positive cells/50 000 cells in peripheral blood. CMV disease was defined as positive CMV cytology or shell vial culture from bronchoalveolar lavage or tissue. Herpetic infections (herpes simplex virus and varicella-zoster virus) were diagnosed on the basis of clinical presentation and/or culture.
Preparative regimen and GVHD prophylaxis Indications for NMA conditioning were age (older than 55 years for sibling HSCT and 45 years for unrelated umbilical cord blood (UCB) HSCT), presence of comorbidities, poor performance status or previous autologous HSCT. Patients 
Statistical analysis
Infection-free survival was calculated from day 0 until infection or death at days 30, 100 and 1 year by using the KaplanÀMeier method. Cumulative incidence 19 was used to estimate risks of infections, infection-related non-relapse mortality and all-cause TRM at 1 year. Infection incidence density was calculated as the number of infectious episodes divided by the number of patient days (pd) at risk multiplied by 1000 (infections/1000 pd) in separate time periods 0-30 days, 31-100 days, 101-365 days and compared using the Mantel-Haenszel w 2 test. Patient and graft characteristics were compared between the NMA and MA groups by using the w 2 test, Fisher's exact test or t-test, as appropriate.
The log-rank test 20 was used to compare the incidence of initial bacterial, viral and fungal infections. Cox proportional hazards models 21 were used to evaluate the risk factors on the first bacterial, viral and fungal infections. Recurrent (including initial and subsequent) bacterial infections were analyzed using the proportional rates model. 22 The following risk factors were considered in regression analyses: recipient age, gender, remission status at time of transplant, year of transplant, prior autotransplant, CMV serostatus of patient and donor, diagnosis (non-Hodgkin's vs Hodgkin's lymphomas), donor type by HLA disparity (matched sibling donor, matched unrelated donor/mismatched related donor, UCB), conditioning regimen (MA vs NMA), and acute GVHD as timeInfections after allotransplantation for lymphoma V Bachanova et al dependent covariate. Conditioning regimen was included in all models. Table 1 details characteristics for 141 transplant recipients with lymphoma conditioned with either an NMA (n ¼ 76) or MA (n ¼ 65) preparative regimen. 5 Patients in the NMA cohort were older (median (range) 48 years (9-66) vs 42 years (4-58); Po0.01), and over a third of patients had relapsed after a prior autologous HSCT (n ¼ 30). Although most MA donors were matched siblings, unrelated partially matched UCB transplants were more common in the NMA cohort. All unrelated donor (URD; MA: n ¼ 3, NMA: n ¼ 6) and four sibling donor HSCT recipients (MA: n ¼ 2, NMA; n ¼ 2) received marrow grafts. Fewer recipients and donors were CMV seropositive in the NMA compared to MA cohort. The median follow-up of surviving patients was 3 years (range 1-4.7 years) in the NMA cohort and 3.2 years (range 1.9-8.8 years) in the MA cohort.
Results
Patient characteristics
Engraftment and GVHD
The NMA patients had a significantly shorter time to engraftment than did MA patients. Median (range) times to ANC 4500/ml were 10 (0-61) and 16 days (11-47; Po0.01), although the proportion of patients experiencing neutropenia beyond 21 days was 15 and 14% for NMA and MA cohorts, respectively. Only one patient in each cohort failed to engraft. There were no deaths in the NMA cohort before engraftment as compared to seven deaths in the MA cohort. The cumulative incidence of acute and chronic GVHD was similar (grades II-IV acute GVHD at 100 days: NMA 58% (45-71%) vs MA 43% (30-56%), P ¼ 0.47; chronic GVHD at 2 years: NMA 55% (41-69%) vs MA 35% (22-48%), P ¼ 0.12). Treatment outcomes for both cohorts were reported elsewhere. 5 Bacterial, viral and fungal infections In the first year post transplantation, the most frequent infections in either cohort were bacterial, followed by viral and fungal (Figures 1a, b and c) . The proportion of patients who were free of bacterial (NMA 31% vs MA 20%; P ¼ 0.37), viral (NMA 38% vs MA 40%; P ¼ 0.62) or fungal infection (NMA 64% vs MA 69%; P ¼ 0.33) during the 1-year follow-up was similar.
Peritransplant infections (days 0-30) From 0 to 30 days post transplantation, all bacterial, viral and fungal infections were markedly less frequent in the NMA cohort when compared to the MA cohort ( Figure 1a) . Bacterial infection occurred in 22% (95% CI 12-31%) and 49% (95% CI 36-62%; Po0.01) of patients in NMA and MA cohorts, respectively. The infection density of all bacterial infections was 2.7-fold lower in the NMA cohort (Po0.0001; Figure 1a) , which was mainly attributed to a fourfold less frequent rate of Gram-positive infections (P ¼ 0.002; Figure 1a ) and a trend toward fewer Gram-negative infections (P ¼ 0.11) following NMA conditioning. Rates of catheter-associated bacteremia and C. difficile colitis were similar in both cohorts (data not shown). To assess the impact of the shorter time to engraftment in the NMA cohort on the risk of bacterial infections, we compared bacterial infections between the two cohorts before and after neutrophil recovery. Before neutrophil engraftment, the NMA cohort had a 53% lower infection rate than the MA cohort (relative risk (RR) ¼ 0.47; 95% CI, 0.21-1.02, P ¼ 0.06). After engraftment, both cohorts have similar rates of bacterial infection (RR ¼ 1.07, 95% CI, 0.72-1.57, P ¼ 0.75). Infections after allotransplantation for lymphoma V Bachanova et al
Peritransplant viral infection developed in 9 and 18% of patients in the NMA and MA cohorts, respectively (Po0.08). Consequently, viral infection density was twofold lower in the NMA group as compared to the MA group (Po0.05; Figure 1a) . CMV antigenemia was the most frequent peritransplant viral infection in both groups (Figure 1a ) but occurred at similar frequency after correction for CMV serostatus of donor-recipient pairs. Figures 2a-c illustrate cumulative incidence of CMV reactivation in three groups (seropositive recipients, seronegative recipients with seropositive donors and seronegative recipients with seronegative donors). We observed fewer early viral infections in the NMA cohort, largely as the result of fivefold lower rates of 'other' non-herpes simplex virus and varicella-zoster virus infections, including HHV6, adenoviruses and enterohepatic viruses (P ¼ 0.06, Figure 1a ).
Fungal infections occurred less frequently than did either bacterial or viral infections in both cohorts. The risk of proven or probable IFI in the first 30 days post transplant was twofold less following NMA as compared to MA conditioning (NMA 3.17 vs MA 5.9 per 1000 pd; P ¼ 0.22, Figure 1a ). The density of invasive aspergillosis was threefold less (NMA 0.5 vs MA 1.6 per 1000 pd; P ¼ 0.25, data not shown).
Early post transplant infections
Between days 31 and 100, the density of bacterial infections remained stable in the NMA cohort, and fell to a similar rate in the MA cohort (P ¼ 0.15; Figure 1b ). Gram-negative pneumonia was the most frequent bacterial infection in the NMA cohort with a threefold higher density as compared to the MA cohort (NMA 2.1 vs MA 0.6 per 1000 pd; P ¼ 0.07), whereas rates of all Gram-negative and Gram- Infections after allotransplantation for lymphoma V Bachanova et al positive bacterial infections were similar in both cohorts (Figure 1b) . Beyond 30 days post allograft, the total viral infection rate and the donor-recipient serostatus adjusted CMV reactivation rate were similar between the cohorts (total viral infections: NMA 9.57 vs MA 7.15 per 1000 pd, P ¼ 0.28; total CMV: 3.85 vs 3.32 per 1000 pd, P ¼ 0.70, Figure 1b and 2a) . Figure 2a illustrates a trend for higher cumulative incidence of CMV reactivation after day 30 in CMV seropositive recipients following the NMA conditioning as compared to the MA conditioning. Recurrent CMV was diagnosed in five patients (NMA: n ¼ 4 vs MA: n ¼ 1; P ¼ 0.76). Four out of the five had acute or chronic GVHD at the time of CMV reactivation. Three patients in each cohort developed CMV disease before day 100 (five pneumonia, one colitis). Co-infections were present in all patients with CMV disease (three Gram-negative bacteria, four other viral). Only one of the six patients with CMV disease survived to 1 year of age.
The IFI density between days 31 and 100 was similar in the NMA cohort (2.43/1000 pd) and the MA cohort, respectively (3.42/1000 pd; P ¼ 0.48; Figure 1b) .
Late post transplant period
During the late post transplant period (days 101-365), bacterial, viral and fungal infections were uncommon in both cohorts. Although the density of bacterial infections was similar, the density of viral infections was lower in the NMA cohort (Po0.088; Figure 1c ), predominantly due to 1.5-fold less frequent herpetic infections (NMA 0.35 vs MA 1.1 per 1000 pd; Po0.02; Figure 1c ). Beyond day 100, CMV reactivated at a very low rate (P ¼ 0.95; Figures 1c  and 2 ). No episodes of CMV disease occurred after day 100. IFI diagnosed after day 100 occurred at a density of 0.77 episodes per 1000 pd following NMA conditioning as compared to 0.31 episodes per 1000 pd in the MA cohort (P ¼ 0.79; Figure 1c ).
Risk factors for infections
The 1-year cumulative incidence of bacterial infection was significantly lower in the NMA cohort (NMA 63% (50-76) vs MA 75% (61-89); Po0.01). However, the 1-year cumulative incidence of viral and fungal infections was similar (viral: NMA 58% (46-70%) vs MA 58% (44-72%), P ¼ 0.47; fungal NMA 32% (22-42) vs MA 28% (17-39%); P ¼ 0.96). In multivariate analysis, NMA conditioning was associated with lower rates of bacterial infections (RR ¼ 0.5 (0.3-0.8); Po0.01; Table 2 ) and did not independently affect the risk of viral and fungal infections. Adjusted for conditioning and compared to the sibling donor grafts, the use of unrelated UCB was associated with similar rates of bacterial and fungal infections and a marginally increased risk of viral infections (RR ¼ 1.8; P ¼ 0.03; Table 2 ). This stands in contrast to URD recipients, who had notably higher rates of bacterial (RR ¼ 2.23; Po0.0001), viral (RR ¼ 2.7; P ¼ 0.01) and fungal infections (RR ¼ 3.3; Po0.01; Table 2 ). As expected, the CMV seropositive recipient and grades III-IV acute GVHD substantially increased the risk of viral infections (RR ¼ 2.4; Po0.01; RR ¼ 2.5; Po0.01).
Infection-related mortality
The IRM was considerably lower at 1 year following NMA conditioning (NMA 9% (3-16%) vs MA 22% (11-40); P ¼ 0.03; Figure 3) . Beyond day 100, we observed a single infection-related death (IFI) in the NMA cohort and five deaths in the MA cohort (IFI two, viral three). Overall, infection-free survival was superior for the NMA cohort at 30 days (68 vs 40%; Po0.01), 100 days (20 vs 17%; P ¼ 0.04) and 1 year following transplant for the NMA cohort (NMA 12% vs MA 9%; P ¼ 0.04). 
Discussion
The NMA HSCT has become a feasible and widely used treatment strategy for relapsed or refractory non-Hodgkin's and Hodgkin's lymphoma patients. 5, 6, [13] [14] [15] Although TRM is reduced following NMA conditioning, infections remain frequent and reflect the complexity of functional immune recovery.
We observed important differences in the etiologies, timing and outcomes of infections in 141 lymphoma patients when comparing cohorts conditioned with NMA and MA regimens. To account for consecutive infectious episodes and the number of days each patient was at risk, we compared infection rates per 1000 patient days. The recipients of NMA conditioning develop substantially fewer peritransplant bacterial infections, non-CMV viral infections and IFI. Notably, the mortality attributable to infections was lower following NMA conditioning. Even though the patients who received NMA conditioning are older, more heavily pretreated, and may have comorbidities that preclude MA conditioning, our results suggest that the rate of infections is lower in the NMA cohort, particularly early post transplant.
The most prominent effect of NMA conditioning is the lower rate of bacterial infections before engraftment. We suggest that the benefits of reduced-intensity conditioning are largely attributed to shortened duration and severity of neutropenia. 10 Given the marked reduction of the Grampositive and Gram-negative infections in the NMA cohort during the first 30 days following transplant but a lack of difference in catheter-associated infections, we hypothesize that the mucosal integrity of the oral cavity and gastrointestinal tract is preserved after NMA conditioning and therefore bacterial bloodstream invasion is less common. These results are in agreement with Junghanss et al. and others, who reported a lower incidence of early bacteremia in NMA allogeneic HSCT patients with a variety of hematologic malignancies. 8, 10, 12, 13 At variance with previous reports of higher incidence non-neutropenic bacterial infections following reduced-intensity conditioning, 23 we observed no significant increase in the rate of postengraftment bacterial infections in the NMA cohort. The intensity of the preparative regimen has a profound effect on the quality and temporal sequence of immune reconstitution and donor engraftment. 15, 24 The effect of donorrecipient chimerism on the development of non-neutropenic post transplant infections merits future analysis.
The CMV reactivation, the most frequent opportunistic viral infection following allotransplant, varies from 15-80% in different series. 9, 11, 16, 23, 25 The recipient's CMV serostatus, the major determinant for CMV reactivation was positive in 45-60% of patients, which is similar to the recent report 26 and reflects the prevalence in our patient population. The difference in CMV reactivation adjusted for serostatus was of marginal significance in the subgroup of CMV seropositive recipients. In contrast to a previous report, 9 CMV recurrences were infrequent and, importantly, we observed no late CMV disease with either conditioning. The risk of fungal infections is similar in the NMA and MA cohorts; therefore, improved diagnostic tools and optimal antifungal prophylaxis are critical for patients conditioned with either regimen. 27 As with most observational studies that analyze patients enrolled over many years, our cohorts have some variability in donor types and transplant characteristics. How- Infections after allotransplantation for lymphoma V Bachanova et al ever, more than 80% of the MA and nearly 70% of the NMA cohort received CY/TBI and Flu/CY/TBI, respectively. Furthermore, GVHD prophylaxis was over 90% uniform in both cohorts. The antimicrobial prophylaxis was identical over the years, although advances in treatment of opportunistic infections and improved supportive care in the last few years may have favorably affected the IRM for patients transplanted more recently. As reported elsewhere, the overall survival of this cohort of patients treated with NMA is the same when compared to MA, in part due to the increased risk of relapse in the NMA cohort. 5 The current analysis describes the effect of conditioning intensity on IRM. This is important because NMA HSCT represents an effective treatment modality for patients who are either too old or otherwise unfit for MA conditioning. Despite increased relapse rates following the NMA regimen, the overall survival of these patients is comparable to younger patients treated with the MA regimen because of decreased TRM and decreased IRM. An NMA conditioning regimen used for patients with lymphoid malignancies is associated with reduction of bacterial, viral and fungal infections early post transplant and results in less infection-related deaths. The continuing risks of post-engraftment bacterial infections, CMV reactivations and IFI infections associated with both NMA and MA conditioning indicate an opportunity for risk-tailored preventive and therapeutic anti-infectious strategies for patients undergoing allotransplantation. These data suggest that functional immune reconstitution is delayed with either conditioning intensity.
